OncLive SOSS

Authors

Alvaro Martinez, MD

Latest:

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Alvin H. Schmaier, MD

Latest:

Dr. Schmaier on Managing Cancer-Associated Thrombosis

Alvin H. Schmaier, MD, professor in the Department of Medicine and the Department of Pathology at Case Western Reserve University School of Medicine, discusses the management of patients with cancer-associated thrombosis.

Aly-Khan Lalani, MD

Latest:

Dr. Lalani on a Study of Neutrophil-Lymphocyte Ratio in RCC

Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses the results of a study investigating neutrophil-lymphocyte ratio (NLR) in patients with renal cell carcinoma (RCC).

Alyssa Dahl, MPH

Latest:

Growing Pains: OCM Results Need Close Look

Darcie Hurteau, MBA, and Alyssa Dahl, PhD, MPH, discuss the growing pains of the Oncology Care Model, a complicated payment program that is still establishing administrative processes.

Alyssa Dahl, MPH, CPH

Latest:

Oncology Care Model Practices Await CMS Report Cards

Alyssa Dahl, MPH, CPH, discusses what to watch for when the CMS releases performance results for the Oncology Care Model.

Aman Bhandari, PhD

Latest:

Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?

Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.

Aman Chauhan, MD

Latest:

Dr. Chauhan on Future Directions With Lutathera in GEP-NETs

Aman Chauhan, MD, discusses future directions with Lutathera in gastroenteropancreatic neuroendocrine tumors.

Latest:

Organizing a Fellows' Career Day

Everybody is aware that career choices in oncology abound these days. But when you ask fellows what job they are interested in once they complete their fellowship, many just don't know-even in their third year.

Amanda Nickles Fader, MD

Latest:

Dr Fader on Letrozole With or Without Paclitaxel and Carboplatin in Ovarian Serous Carcinoma

Amanda Nickles Fader, MD, discusses the randomized, phase 3 NRG-GY019 trial evaluating letrozole with or without paclitaxel and carboplatin in patients with stage II to IV primary low-grade serous carcinoma of the ovary or peritoneum.

Latest:

Navigating the Job Search for Surgical Oncology Fellows

As the end of training approaches, the job hunt begins. Below are some tips to follow to make the job-hunting process easier.

Amber Orman, MD

Latest:

A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures

Latest:

Decision Support Systems in Oncology: Are we there yet?

The push for clinical decision support technology in medicine is a logical consequence of our experiences as consumers and the need for intelligent support at the bedside.

Latest:

Dr. Karam on the Role of Debulking Surgery in Recurrent Ovarian Cancer

Amer Karam, MD, discusses determining whether to use debulking surgery after recurrence in ovarian cancer.

Amer M. Zeidan, MD

Latest:

How Do I Keep Up With the Literature?

As an oncology fellow pursuing an academic career, one of the major challenges Amer M. Zeidan faces is balancing clinical duties and research activities.

Amer Zeidan, MBBS, MHS

Latest:

Comparison of Oral vs Intravenous Hypomethylating Agents in the Treatment of MDS

Panelists discuss how oral decitabine/cedazuridine showed encouraging efficacy in patients with myelodysplastic syndromes (MDS) with TP53 mutations, suggesting this oral formulation could be particularly beneficial for this historically difficult-to-treat molecular subgroup.

Amer Zeidan, MD

Latest:

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007

Dr. Amer Zeidan presents interim Phase 1a results from the KOMET-007 trial, demonstrating the safety and robust clinical activity of ziftomenib combined with intensive chemotherapy (7+3) in newly diagnosed adverse-risk NPM1-mutated and KMT2A-rearranged acute myeloid leukemia, highlighting high response rates and promising survival outcomes.

Ami S. Bhatt, MD, PhD, Franklin W. Huang, MD, PhD

Latest:

Organization Rallies Global Oncology Community to Eliminate Cancer Health Disparities

Today, more than half of new cancer cases and over two-thirds of cancer deaths occur in low- and middle-income countries.

Ami Vijay Desai, MD

Latest:

Dr. Desai on Phase I Study of Entrectinib in Solid Tumors

Ami Vijay Desai, MD, assistant professor of Pediatrics, University of Chicago Comer Children's Hospital, discusses the design of a phase I study testing entrectinib in patients with solid tumors.

Amin J. Mirhadi, MD

Latest:

Dr. Mirhadi on Patient Populations of Lung Cancer Optimal for Radiation

Amin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.

Amir Ahmed Toor, MD

Latest:

Computer Model Personalizes Donor Selection for Stem Cell Transplants

Investigators at Virginia Commonwealth University Massey Cancer Center are developing dynamical models that may allow clinicians to move beyond simple human leukocyte antigen matching to personalize immunosuppressive regimens and thus improve donor selection.